Loading organizations...
XenoPort Inc. was a biopharmaceutical company developing and commercializing internally discovered therapeutics. It utilized a proprietary prodrug platform, chemically modifying compounds to enhance pharmacological properties like absorption and distribution. Its lead product, HORIZANT (gabapentin enacarbil) extended-release tablets, treated moderate-to-severe restless legs syndrome (RLS) and postherpetic neuralgia (PHN).
Founded in 1999 by Dr. Ronald W. Barrett, Dr. William J. Dower, and Dr. Mark A. Gallop, XenoPort was established on the insight that modifying small molecules into prodrugs could optimize pharmacokinetics. This improved drug efficacy and patient tolerability, with Dr. Barrett later leading as President and CEO.
XenoPort's products targeted patients with RLS and PHN, and explored applications for psoriasis and multiple sclerosis. The company envisioned leveraging its innovative prodrug technology to create differentiated product candidates, addressing unmet medical needs through enhanced drug delivery and improved profiles.
Xenoport has raised $97.0M across 3 funding rounds.
Xenoport has raised $97.0M in total across 3 funding rounds.
Xenoport has raised $97.0M in total across 3 funding rounds.
Xenoport's investors include Venrock, ARCH Venture Partners.
Xenoport has raised $97.0M across 3 funding rounds. Most recently, it raised $37.0M Series C in January 2004.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2004 | $37M Series C | — | Venrock | Announced |
| May 1, 2002 | $44M Series B | — | ARCH Venture Partners, Venrock | Announced |
| Jan 1, 2000 | $16M Series A | — | ARCH Venture Partners, Venrock | Announced |
XenoPort, Inc. is a biopharmaceutical company that develops and commercializes product candidates targeting neurological and other disorders, primarily in the United States.[1][2][3] Its lead product, HORIZANT (gabapentin enacarbil) extended-release tablets, treats moderate-to-severe primary restless legs syndrome and postherpetic neuralgia in adults, while the pipeline includes XP23829 (in Phase III for psoriasis and multiple sclerosis), arbaclofen placarbil (Phase II for spasticity in multiple sclerosis), and XP21279 (Phase II completed for Parkinson's disease).[1] XenoPort serves patients with neurological conditions through licensed partnerships, such as with Indivior PLC, Astellas Pharma, and Glaxo Group Limited, addressing unmet needs in disorder management via prodrug technologies that leverage the body's natural transport mechanisms.[1][2][3] The company, based in Santa Clara, California, became a subsidiary of Arbor Pharmaceuticals, LLC on July 1, 2016, marking a shift from independent operations.[1][4]
XenoPort was founded in 1999 in Santa Clara, California, by Dr. Ronald Barrett, who served as Chief Scientific Officer from 1999 to 2001 before becoming CEO in 2001 and joining the Board in 2007.[1][2] Barrett's background includes senior roles at Affymax Research Institute (acquired by Glaxo Wellcome), providing expertise in research and development that shaped XenoPort's focus on internally discovered prodrug candidates for neurological disorders.[2] Early traction came through HORIZANT's U.S. approval and marketing, alongside license agreements for global development, such as Regnite in Japan with Astellas Pharma.[1] A pivotal moment was the 2016 acquisition by Arbor Pharmaceuticals, integrating XenoPort as a subsidiary and expanding its commercial reach.[1]
XenoPort rides the wave of neurological disorder therapeutics, focusing on prodrugs to improve drug delivery amid rising demand for treatments in restless legs syndrome, multiple sclerosis, psoriasis, and Parkinson's—conditions affecting millions globally.[1][2] Timing aligns with advances in biopharma transport mechanisms post-2010s, when HORIZANT gained approval, capitalizing on unmet needs in chronic neurological management.[1][3] Market forces like aging populations and increasing neurological disease prevalence favor its portfolio, while the 2016 Arbor acquisition amplified influence by integrating into a larger pharma ecosystem for scaled commercialization.[1][4] XenoPort contributes by pioneering substrate-based prodrugs, influencing biotech innovation in targeted therapies and partnership models.[2][3]
Post-2016 acquisition, XenoPort's trajectory hinges on Arbor's integration of its pipeline, with XP23829 poised for potential approvals in psoriasis and multiple sclerosis if Phase III succeeds, alongside advancements in spasticity and Parkinson's candidates.[1] Evolving trends like precision neurology and prodrug optimization will shape progress, potentially expanding via new licenses or acquisitions in a consolidating biopharma sector.[1][2] Its influence may grow through Arbor-driven commercialization, solidifying XenoPort's legacy in neurological innovation from a Santa Clara startup to a key subsidiary player.[1]
